BULLETIN OF THE
Communication
KOREAN CHEMICAL SOCIETY
264.7
macrophages
compared
to
Malvidin
In conclusion, we synthesized 48 benzofuranone deriva-
tives and tested for LPS-stimulated ROS production in
RAW 264.7 macrophages. Compounds 31, 42 and 46 with
hydroxy at 6-position of benzofuranone exhibited potent
inhibitory activity (IC50 = 6.25–6.80 μM) against LPS-stimu-
lated ROS production in RAW 364.7 macrophages as com-
pared to reference compound. These results showed
importance of hydroxyl group along with ortho-
trifluoromethoxyl, para-pyridyl, and para-thiophenyl moie-
ties at phenyl ring of aurone derivatives. These findings
would provide useful information for the group of
researchers working on the development of anti-inflamma-
tory agents.
(IC50 = 9.0 Æ 0.8 μM), positive control and data are pres-
ented in Tables 1 and 2.11
From series A, compounds 1–24 bearing no hydroxyl
group at 6-position of ring A exhibited no toxicity against
RAW 264.7 macrophages. Among 24 aurone derivatives
only aurone 15 bearing chloro group at para- position of
B-ring showed comparable suppression of ROS production
(IC50 = 9.55 μM) in RAW 264.7 macrophage to positive
control, Malvidin. Therefore, except compound 15, non-
hydroxylated aurones are found to exhibit insignificant
inhibitory activity against LPS-stimulated ROS production
in RAW 264.7 macrophages.
As shown in Table 2, most of the C-6 hydroxy-substituted
compounds (series B, 25–48) demonstrated weak inhibition
of ROS production in RAW 264.7 macrophages. Com-
pounds possessing ortho-trifluoromethoxyphenyl group (31),
para-pyridyl group (42) and para-thiophenyl group (46)
exhibited better LPS-stimulated ROS production inhibitory
activity than malvidin with IC50 = 6.80, 6.41, and 6.25 μM,
respectively. Changing the position of trifluoromethoxy
group from ortho- to para-position in B-ring of 6-hydroxyl-
ated aurone results in compound 33 which exhibited higher
toxicity and no inhibitory activity. Similar to compound 33,
compound 28 possessing ortho-trifluoromethylphenyl moiety
also showed toxicity while all other prepared compounds are
confirmed to be nontoxic.
Previously our group reported that among the eight com-
pounds (13–15, 23, 24, 37–39), compound 24 showed sig-
nificant inhibition of TNF-α induced ROS production in
HT-29 cell.10 Surprisingly, the same eight compounds did
not exhibit any inhibitory effect on LPS-stimulated ROS
production in RAW 264.7 macrophages which may be due
to different target and mechanism.
As far as SAR study is concerned, insignificant inhibi-
tory activity (IC50 > 10 μM) demonstrated by most of the
compounds resulted in difficulty to withdraw a concrete
SAR. However, it is interesting to note that the presence of
6-hydroxybenzofuran-3(2H)-one pharmacophore in three
compounds (31, 42, and 46) has direct impact on their
higher inhibitory activity against ROS production stimu-
lated by LPS in RAW 264.7 macrophages. This indicates
the importance of hydroxyl group at 6-position of
benzofuranone to improve the ROS inhibitory activity. In
addition, the significant inhibitory results shown by the
these compounds suggested the presence of ortho-
trifluoromethoxyl, para-pyridyl, and para-thiophenyl moie-
ties at phenyl ring of aurone derivatives is advantageous for
the inhibition of ROS production as shown in Figure 3.
Acknowledgments. This work was supported by the
National Research Foundation of Korea (NRF) grant funded
by the Korea government (MSIT) NRF-2017R1A2B2003944.
Supporting Information. Additional supporting informa-
tion may be found online in the Supporting Information
section at the end of the article.
References
1. Z. Dong, Y. Yuan, Int. J. Mol. Sci. 2018, 41, 3405.
2. J. A. Lee, H. Y. Song, S. M. Ju, S. J. Lee, H.-J. Kwon, W. S.
Eum, S. H. Jang, S. Y. Choi, J. Park, Exp. Mol. Med. 2009,
41, 629.
3. H. Chen, X. D. Qi, P. Qiu, Aust. J. Pharm. 2014, 9, 501.
4. C. Zwergel, F. Gaascht, S. Valente, M. Diederich, D. Bagrel,
G. Kirsch, Nat. Prod. Commun 2012, 7, 1934578X1
200700322.
5. H. L. Yadav, P. Gupta, R. Pawar, P. Singour, U. Patil, Med.
Chem. Res. 2011, 20, 461.
6. M. Roussaki, S. Costa Lima, A.-M. Kypreou, P. Kefalas, A.
Cordeiro da Silva, A. Detsi, Int. J. Med. Chem. 2012, 2012,
196921.
7. A. Shrestha, H. J. Oh, M. J. Kim, N. T. Pun, T. B. Thapa
Magar, G. Bist, H. S. Choi, P.-H. Park, E.-S. Lee, Eur.
J. Med. Chem. 2017, 133, 121.
8. T. Nakayama, T. Sato, Y. Fukui, K. Yonekura-Sakakibara, H.
Hayashi, Y. Tanaka, T. Kusumi, T. Nishino, FEBS Lett.
2001, 499, 107.
9. N. Nenadis, M. P. Sigalas, J. Phys. Chem. A., 2008, 112,
12196.
10. T. M. Kadayat, S. Banskota, P. Gurung, G. Bist, T. B. T.
Magar, A. Shrestha, J.-A. Kim, E.-S. Lee, Eur. J. Med. Chem.
2017, 137, 575.
11. E. Bognar, Z. Sarszegi, A. Szabo, B. Debreceni, N.
Kalman, Z. Tucsek, B. Sumegi, F. Gallyas, PLoS One
2013, 8, e653.
Bull. Korean Chem. Soc. 2021, Vol. 42, 372–375
© 2021 Korean Chemical Society, Seoul & Wiley-VCH GmbH
375